Clinical Trial: A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412691) titled 'A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases' on Feb. 09.

Brief Summary: This is the first-in-human study of BG-A3004. The study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of BG-A3004 after single and multiple doses administered in different dose levels in healthy participants (Part A) and patients with immune-mediated skin diseases (Part B), respectively.

Study details include:

* The study duration will be approximately 3 years.

* The treatment duration will be 1 dose for Part A and 4 doses for Part...